Idiopathic Pulmonary Fibrosis| A Pipeline Analysis Report 2018 by Technavio | Financial Buzz

Idiopathic Pulmonary Fibrosis| A Pipeline Analysis Report 2018 by Technavio

Technavio
has announced their latest pipeline analysis report on the idiopathic
pulmonary fibrosis market. The report includes a detailed
analysis of the pipeline molecules under investigation within the
defined data collection period to treat idiopathic pulmonary fibrosis.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180622005553/en/

Technavio has published a new report on the drug development pipeline for idiopathic pulmonary fibrosis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market during the forecast period.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Idiopathic pulmonary fibrosis: Market overview

Idiopathic pulmonary fibrosis is a lung disorder that affects lung
tissues, making them thick, stiff, and scarred. The scarring of these
tissues gets worse over time, making it difficult for the person to
breathe. With low levels of oxygen supply to the brain and other organs,
tissues tend to lose their efficiency. IPF is usually found in
middle-aged and older people. However, the severity of the disease may
vary from person to person. IPF can be caused due to cigarette smoking,
viral infections, and family history.

According to a senior analyst at Technavio for research on infectious
and rare diseases, “IPF is one of the interstitial lung diseases.
Presently, there is no cure for IPF. However, it can be treated with
medication to ensure long-term survival. Researchers are finding new
drugs and treatments for IPF, owing to technological advancements. The
rate at which IPF progresses varies. It is stable for years in some
patients and may rapidly worsen in some patients.”

Idiopathic pulmonary fibrosis: Segmentation
analysis

This market research report segments the Idiopathic pulmonary fibrosis
market based on therapies employed that includes (monotherapy,
combination therapy, and unknown), RoA (oral, inhalation, intravenous,
subcutaneous, and undisclosed), therapeutic modalities (small molecules,
monoclonal antibodies, recombinant protein, stem cell, protein,
antibody, and undisclosed), targets for drugs under development
(integrin alphaV 6, GSNOR, CTGF, others, and undisclosed), drugs under
development (discovery, pre-clinical, phase I, phase I/II, phase II, and
phase III), MoA (GSNOR inhibitor, integrin alphaV 6 inhibitor, others,
and undisclosed), and recruitment status (completed, recruiting, active
not recruiting, not yet recruiting, and undisclosed). It provides an
in-depth analysis of the prominent factors influencing the market,
including drivers, opportunities, trends, and industry-specific
challenges.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180622005553/en/